GS
ACAD icon

GTS Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

GTS Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,712
Closed -$226K – 1244
2024
Q3 		$226K Sell
14,712
-12,153
-45% -$203K ﹤0.01% 3555
2024
Q2 		$437K Sell
26,865
-30,711
-53% -$496K ﹤0.01% 2809
2024
Q1 		$1.06M Buy
57,576
+39,588
+220% +$981K ﹤0.01% 1942
2023
Q4 		$563K Sell
17,988
-40,323
-69% -$963K ﹤0.01% 2694
2023
Q3 		$1.22M Buy
+58,311
New +$1.58M ﹤0.01% 1859

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GTS Securities's ACAD Position: Q4 2024 in Review

GTS Securities sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 14,712 shares — an estimated $226K sold.

GTS Securities first reported a position in ACAD in Q3 2023 and held it in 5 quarters. The position peaked at $1.22M in Q3 2023. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • GTS Securities reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 14,712 Acadia Pharmaceuticals shares in Q4 2024, an estimated $226K.
  • GTS Securities first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • GTS Securities's Acadia Pharmaceuticals position peaked at $1.22M in Q3 2023.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.